In early studies, the IGFs were shown to enhance 3D growth of glioblastoma (21) and more recently, high IGF-IR expression levels were identified as an independent prognostic factor associated with shorter survival, a poorer response to temozolomide (4) and resistance to anti-EGFR (24) and anti-PDGFR (25) treatments in GBM patients. Here, PDGFRB is linked to glioblastoma.